Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556576 | 0.79 | TACR1 (0.37) | RENKCNH2CYP3A4OPRD1OPRK1 | |
| SCHEMBL3099564 | 0.78 | ALK (0.41) | RENKCNH2CYP3A4 | |
| SCHEMBL3099550 | 0.78 | ALK (0.41) | RENKCNH2CYP3A4 | |
| SCHEMBL555641 | 0.76 | TACR1 (0.37) | RENKCNH2CYP3A4 | |
| SCHEMBL556577 | 0.76 | REN (0.37) | RENKCNH2CYP3A4 | |
| SCHEMBL556775 | 0.75 | TACR1 (0.36) | RENKCNH2CYP3A4 | |
| SCHEMBL556776 | 0.73 | REN (0.35) | RENKCNH2CYP3A4 | |
| SCHEMBL557038 | 0.72 | ALDH1A1 (0.45) | RENKCNH2CYP3A4KMT2AALDH1A1 | |
| SCHEMBL534595 | 0.71 | OPRK1 (0.40) | OPRD1OPRK1KMT2ALMNAMEN1 | |
| SCHEMBL534508 | 0.69 | MEN1 (0.37) | OPRD1OPRK1KMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | REN 1/4885KCNH2 1198/4885CYP3A4 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.